Sorin Group has announced FDA clearance for Memo 3D ReChord, an innovative semi-rigid annuloplasty ring for repair in patients with...
AbbVie released the first phase III results for the investigational three direct-acting-antiviral (3D) regimen (ABT 450/r and ABT 267 and...
AbbVie released phase III results for the investigational three direct-acting-antiviral (3D) regimen plus ribavirin in patients with chronic, genotype 1...
Alcon, the global leader in eye care and a division of Novartis, launches the Ngenuity 3D Visualization System, a platform...
The FDA has approved the Selenia Dimensions System,from Hologic Inc., the first X-ray mammography device that provides three-dimensional (3-D) images...
The FDA has approved the Bio-Rad BioPlex 2200 HIV Ag-Ab assay, the first FDA-approved diagnostic that differentiates between HIV-1 antibodies,...
Astellas Pharma Inc. and Iveric bio, Inc. announced that, the Companies have entered into a definitive agreement under which Astellas through Berry Merger Sub, Inc. a wholly-owned subsidiary of Astellas US Holding, Inc., has agreed to acquire 100% of the outstanding shares of Iveric Bio for US$40.00 per share in cash for a total equity value of approximately US$5.9 billion.
Bristol Myers Squibb and 2seventy bio, Inc. announced that the FDA Oncologic Drugs Advisory Committee (ODAC) voted positively (8-3) that Abecma (idecabtagene vicleucel) demonstrated a favorable benefit/risk profile for patients with triple-class exposed relapsed or refractory multiple myeloma based on results from the pivotal Phase III KarMMa-3 study, including the key secondary endpoint of overall survival.
bluebird bio, Inc. announced its intent to separate its severe genetic disease and oncology businesses into differentiated and independent publicly traded companies.